SCHEMBL1756263

SCHEMBL1756263

COC(=O)C(NC(=O)c1ncc(-c2ccc(N)cc2)s1)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 12/20 0.50
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TACR3 P29371 1/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756253 0.84 DGAT1 (0.47) DGAT1TAS1R3TAS1R1MMP2MMP9
SCHEMBL1756233 0.81 DGAT1 (0.64) DGAT1MEN1KMT2ASMN1; SMN2
SCHEMBL1756236 0.81 DGAT1 (0.64) DGAT1MEN1KMT2ASMN1; SMN2
SCHEMBL1756218 0.80 DGAT1 (0.53) DGAT1TACR3ALDH1A1MAPT
SCHEMBL1756220 0.80 DGAT1 (0.50) DGAT1TACR3HDAC1MEN1ALDH1A1
SCHEMBL1756234 0.80 DGAT1 (0.68) DGAT1
SCHEMBL1756228 0.79 DGAT1 (0.82) DGAT1
SCHEMBL1756222 0.79 MEN1 (0.53) DGAT1HDAC1HDAC6MEN1GAA
SCHEMBL1756196 0.79 TACR3 (0.46) TAS1R3TAS1R1TACR3MEN1NPC1
SCHEMBL1761476 0.78 TAS1R3 (0.59) TAS1R3TAS1R1TACR3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT DGAT1 1/4885TAS1R3 2623/4885TAS1R1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.